<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **PROSD-2**  
External request: Submission from Myriad Genetic Laboratories, Inc.  
Replace “History and Physical” with “Family history of BRCA1 / 2 mutations. Replace “Family history” with “Family history and genetic risk assessment.” Include footnotes. | Panel consensus supported modifying the bullet and including a footnote. The bullet reads “Family or personal history of BRCA 1 / 2 mutations.” The new footnote states “If there is a known or suspected cancer susceptibility gene, referral to a cancer-genetics professional is recommended. BRCA 1 / 2 pathogenic mutation carriers are associated with an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. Information regarding BRCA 1 /1 gene status should be used as part of the discussion about prostate cancer screening.”  
See Submission for references | YES NO ABSTAIN ABSENT |
| **PROSD-3**  
External request: Submission from MDx Health, Inc  
Recommend inclusion of the SelectMDx test within the evaluation of and indications for biopsy. | Panel consensus did not support inclusion of the SelectMDx test in this version of the guidelines.  
See Submission for references | 0 17 0 11 |